Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:28:30.804Z.
Calculation as of: 2026-10-06T16:28:30.804Z.
Quote observation: 2026-10-06T16:25:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a212b8c45fb170636f79061a8993a9d466e21915543081357b5b59dac86f944c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$308.38M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$299.52M
EBITDA Yield
N/A
TTM Avg
6.62%
3Y Avg
6.62%
5Y Avg
6.62%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avita Medical Inc. (RCEL) | $320.74M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.85M | 3.60% | 3.79% | 2.88% | 2.88% |
| CapsoVision, Inc. (CV)vs › | $324.01M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $317.88M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $324.71M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $333.02M | 11.53% | 6.91% | 6.91% | 10.15% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.38M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $299.52M | N/A | 6.62% | 6.62% | 6.62% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.61M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute